共查询到20条相似文献,搜索用时 343 毫秒
1.
Tsavaris N Kosmas C Skopelitis E Gennatas K Zorbala A Papas P Gouveris P Antypas G Rokana S Tzelepis G 《Lung》2005,183(6):405-416
The efficacy of the docetaxel–carboplatin combination chemotherapy was studied in various phase II studies. Based on these
data we aimed to test the regimen in previously untreated patients with advanced advanced non-smoking lung cancer (NSCLC)
with docetaxel 80 mg/m2 a standard dose of carboplatin at AUC = 5, in an attempt to define the efficacy and tolerability of the combination in
an open-label phase II study. Patients with histologically confirmed advanced NSCLC stage IIIB and IV were candidates for
the present study. Docetaxel was administered at 80 mg/m2 over 1 h by intravenous (IV) infusion followed by carboplatin AUC = 5 in 30 min IV infusion, both on day 1, and recycled
every 21 days. Sixty patients received 263 courses of therapy in total; 231/263 (88%) were administered according to the planned
doses, and 48/60 (80%) patients received chemotherapy without decrement of the dose; 32/263 (12%) of the courses were administered
with a 10%–30% dose reduction. Complete responses (CR) were seen in 5 patients (8.3%) and partial responses (PR) in 16 patients
(26.7%) for an overall response rate of 35%. Median duration of response was 7.5 months [95% confidence interval (CI)-7.1–7.9],
time to progression (TIP) 11.5 months (95% CI-8.2–14.8), median overall survival (OS) 15.0 months (95% CI-10.8–19.2). One-year
survival was 61.7%. Toxicity was acceptable; it was calculated according to the administered cycles and was mainly neutropenia:
grade 3, 9% and grade 4, 2%; anemia: grade 3, 8%; nausea and vomiting: grade 3, 8%. The outpatient regimen of docetaxel–carboplatin
is effective with acceptable toxicity in patients with advanced NSCLC. 相似文献
2.
Takeshi Terashima Tatsu Matsuzaki Rika Ogawa Asuka Naitou Tetsuo Morishita Akitoshi Ishizaka 《Nihon Kokyūki Gakkai zasshi》2008,46(7):516-521
The efficacy and toxicity of treatment with carboplatin (AUC= 5)+ docetaxel (70mg/m2) were analyzed retrospectively in 27 elderly patients with advanced non-small-cell lung cancer (NSCLC) aged 70 years or more. The median age of the patients was 74 years (range, 70-83 years). The performance status (ECOG), clinical stage, and tumor histology in the patients were as follows: PS: PS 0, 12 patients; PS 1, 11 patients; PS 2, 4 patients; disease stage: stage IIIA, 5 patients; stage IIIB, 11 patients; stage IV, 11 patients; tumor histology: adenocarcinoma, 18 patients; squamous cell carcinoma, 9 patients. The median number of treatment cycles administered was 4. The median survival time was 11.1 months and the 1-year survival rate was 40.7%. The response rate was 33.3%. The major toxicities were leukopenia and neutropenia; grade 3/4 neutropenia occurred in 22 patients (81.5%). Nonhematologic toxicities were generally mild, including grade 3 anorexia in 13 patients (48.1%) and grade 3 febrile neutropenia in 9 patients (33.3%). No treatment-related deaths were observed. Thus, it was concluded that the combination of carboplatin + docetaxel is a feasible, well-tolerated, and effective regimen for fit elderly patients with NSCLC. Prospective studies comparing carboplatin + docetaxel with third-generation single-agent chemotherapy or non-platinum-based combination chemotherapy are needed to confirm the efficacy and safety of this drug combination. 相似文献
3.
多西他赛联合卡铂治疗老年晚期非小细胞肺癌临床观察 总被引:1,自引:0,他引:1
目的观察多西他赛(docetaxel)联合卡铂(carboplatin)治疗老年晚期非小细胞肺癌的临床疗效及毒副反应。方法老年晚期非小细胞肺癌患者共40例,多西他赛用量75mg/m^2,每天静脉滴注,同时配伍卡铂AUC=5mg·ml^-1·min^-1,每天静脉滴注。21~28d为1个疗程,每例患者至少接受2个疗程的治疗。结果40例患者均可评价疗效,无完全缓解病例(CR),15例获部分缓解(PR),20例稳定(SD),5例疾病进展(PD),总有效率为37.5%(15/40),其中位疾病进展时间为4.5个月,中位生存时间10.2个月(3~20个月),1年生存率为45.1%。毒性反应主要有骨髓抑制、恶心、呕吐和腹泻以及白细胞下降导致的发热等。但患者多为Ⅰ、Ⅱ度反应,耐受良好。结论多西他赛联合卡铂是一种对老年晚期非小细胞癌有效的治疗方法,毒性反应轻,临床使用安全。 相似文献
4.
Aguiar Bujanda D Bohn Sarmiento U Cabrera Suárez MA Pavcovich Ruiz M Limeres González MA Aguiar Morales J 《Journal of cancer research and clinical oncology》2006,132(5):332-338
Purpose: To assess the efficacy and the toxicity of a new combination of epirubicin, cyclophosphamide and paclitaxel as neoadjuvant
chemotherapy for breast cancer. Methods: Patients with stage II and III breast cancer received 3–4 cycles of epirubicin 75 mg/m2 plus cyclophosphamide 600 mg/m2 on day 1, and paclitaxel at a dose of 100 mg on days 1, 8, 15 and 22 on a 28-day cycle. Results: Forty-nine patients were enrolled in the study. Stage II was present in 16 patients (32.7%) and stage III in 33 patients
(67.3%). Relevant toxicities were nausea/vomiting grades III–IV in 6 patients (12.2%) and neutropenia grade III–IV in 33 patients
(67.3%). The overall clinical response rate was 83.7%. Partial response was observed in 25 patients (51%), complete response
in 16 patients (32.7%), stable disease in 7 patients (14.3%) and progression in 1 patient. Thirty-three non-inflammatory breast
cancer patients underwent surgery, 29 with breast-conserving surgery (87.9%). Pathological complete response was found in
5 patients (15.1%). Conclusions: The combination of epirubicin, cyclophosphamide and weekly paclitaxel as given in this study is safe and shows good activity
in the neoadjuvant setting of stage II and III breast cancer patients. 相似文献
5.
Haiping Jiang Xiaochen Zhang Jing Chen Ling Zhang Jianping Xiong Lin Zhong Feng Yu Jiong Qian Lanfang Yu Xiaoting Wang Genming Shi Jing Deng Nong Xu 《Journal of thoracic disease》2014,6(2):79-85
Background
Weekly docetaxel demonstrated similar efficacy but better tolerability than standard triweekly docetaxel, and carboplatin was less nephrotoxic, neurotoxic and emetogenic than cisplatin. This study aimed to evaluate the efficacy and safety of weekly docetaxel with carboplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC).Methods
Forty-three Chinese patients have been included. Patients were administered docetaxel at a dose of 35 mg/m2 on days 1, 8, 15 and carboplatin at an area under the curve (AUC) 5 on day 1 every 28-day cycle (maximum six cycles).Results
Of the 43 eligible patients, the assessed overall response rate (RR) was 30.2% with 30.2% partial response (PR) in 13 patients, 48.8% stable disease (SD) in 21 patients and 20.9% progressive disease (PD) in 9 patients. The estimated median progression free survival and median overall survival (OS) time were respectively, 120 days (95% CI: 80-160 days) and 340 days (95% CI: 224-456 days) with the patients surviving of 46.5% (95% CI: 31.6-61.4%) at one year and 20.0% (95% CI: 7.1-33.3%) at two years. The major grade 3/4 hematological toxicities were included leucocytopenia in 6 patients (13.9%) and neutropenia in 8 patients (18.6%). One patient (2.3%) suffered grade 1 febrile neutropenia. All grade of the nonhematological toxicities, such as nausea, vomiting, alopecia and fatigue held the proportion of 48.8% (grade 3/4 4.6%), 27.9%, 55.8% and 53.5% (grade 3/4 9.3%), respectively.Conclusions
The combination of weekly docetaxel and carboplatin showed feasible efficacy with acceptable hematologic toxicities for advanced lung cancer. 相似文献6.
Keisuke Kubota Ken-ichi Mafune Kazuhiko Yamada Hideomi Yamashita Junko Kuroda Susumu Aikou Michio Kaminishi 《Esophagus》2009,6(3):183-187
In an attempt to improve survival of patients with locally advanced esophageal cancer, chemoradiotherapy consisting of cisplatin,
5-fluorouracil (5-FU), and irradiation has recently been used. For such patients, concurrent chemoradiotherapy using docetaxel
in combination with cisplatin and 5-FU has been introduced and is under evaluation. We herein report an esophageal cancer
patient with concomitant distant lymph node metastasis in whom a complete response was achieved by chemoradiation therapy.
A 46-year-old man was diagnosed as having stage IV A esophageal cancer with synchronous bulky metastasis in the celiac lymph
node, and concurrent chemoradiotherapy was started. Chemotherapy consisting of docetaxel (30 mg/m2 on days 1, 8), cisplatin (60 mg/m2 on day 1), and 5-FU (200 mg/m2/day, continuous infusion on days 1–14) was performed for 2 cycles. At the same time, irradiation therapy (1.8 Gy/day on 1–5
days every week for 6 weeks) was employed for both local and metastatic lesions. Although the patient experienced severe hematological
toxicity throughout the course, chemoradiotherapy resulted in complete regression of both local and metastatic disease. Subsequently,
he was followed as an outpatient without any maintenance therapy, and he has been free of disease for 38 months after completion
of the combination therapy. Thus, concurrent chemoradiotherapy may be effective for esophageal cancer, even with visceral
metastasis. 相似文献
7.
培美曲塞联合卡铂治疗老年晚期非小细胞肺癌临床观察 总被引:1,自引:0,他引:1
目的观察培美曲塞(pemetrexed)联合卡铂(carboplatin)治疗老年晚期非小细胞肺癌的临床疗效及毒副反应。方法老年晚期非小细胞肺癌患者共46例,培美用量75ms/m^2,每天静脉滴注,同时配伍卡铂AUC=5mg·ml^-1·min^-1,每天静脉滴注。21天为1个疗程,每例患者至少接受2个疗程的治疗。结果46例患者均可评价疗效,无完全缓解病例(CR),21例获部分缓解(PR),20例稳定(SD),5例疾病进展(PD),总有效率为45.6%(21/46),其中位疾病进展时间为4.7个月。中位生存时间10.3个月(3-20个月),1年生存率为52.2%。毒性反应主要有骨髓抑制、恶心、呕吐和腹泻以及白细胞下降导致的发热等。但患者多为Ⅰ、Ⅱ度反应,耐受良好。结论培美曲塞联合卡铂是一种对老年晚期非小细胞癌有效的治疗方法,毒性反应轻,临床使用安全。 相似文献
8.
Xiuyi Zhi Wen Gao Baohui Han Yue Yang Hui Li Deruo Liu Changli Wang Gong Min Hao Long James R. Rigas Mark Carey Thierry Jahan Amanda Sammann Joseph Reza Daoyuan Wang Michael J. Mann David M. Jablons Jianxing He for the China Clinical Trials Consortium 《Journal of thoracic disease》2013,5(5):578-584
Background
To evaluate the safety and tolerability of docetaxel/carboplatin regimen in the post-operative setting of patients with non-small cell lung cancer (NSCLC).Methods
Enrolment of 133 patients with stage Ib - IIIa NSCLC was undertaken in an open-label, single arm study to assess the safety and tolerability of docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent. The primary endpoint of the study was safety, as reflected by a febrile neutropenia rate of <10%. Other endpoints assessed protocol compliance and the impact of minimally invasive surgical technique.Results
Patient accrual was completed at 1 center in the US and 10 centers in China in <6 months. Febrile neutropenia complicated treatment in 12 patients (9.0%), below the predetermined safety threshold of 14 patients. Four VATS and 8 open thoracotomy patients experienced febrile neutropenia (P=0.26). Completion of the three-cycle adjuvant regimen was achieved in 86% (95% CI, 77-95%) of patients. Sixty-two of 66 VATS patients compared to 53 of 67 open thoracotomy patients received all three doses according to protocol (P<0.01). Thirteen serious adverse events (9.8%) and no deaths were attributed to the study regimen.Conclusions
In this rapidly accrued study, docetaxel and carboplatin were well-tolerated in the adjuvant treatment of NSCLC. Adjuvant treatment compliance was higher among patients undergoing a minimally invasive surgical approach. (ClinicalTrials.gov number ).KEYWORDS : NCT00883675Non-small cell lung cancer, adjuvant chemotherapy, docetaxel, carboplatin 相似文献9.
Shiozawa M Sugano N Tsuchida K Morinaga S Akaike M Sugimasa Y 《Journal of cancer research and clinical oncology》2009,135(3):365-370
Purpose The aim of this study was to determine the maximum tolerated dose, recommended dose and dose-limiting toxicities of irinotecan
(CPT-11) plus S-1 in advanced colorectal cancer.
Methods S-1 was administered orally at 80 mg/m2 per day for 14 consecutive days followed by a 2-week rest. CPT-11 was given intravenously on days 1 and 15 of each course,
at an initial dose of 80 mg/m2 per day, stepping up to 100, 120 or 150 mg/m2 per day. Courses were repeated every 4 weeks, unless disease progression or severe toxicities were observed.
Results A total of 21 patients were entered in this study. The maximum tolerated dose of CPT-11 was considered to be 150 mg/m2, because 2 of 3 patients developed dose-limiting toxicities such as leukopenia, neutropenia, diarrhea and anorexia. The recommend
dose of CPT-11 was set at 120 mg/m2. Tumor response rate was 42.8% and median progression-free survival time was 10 months (95% confidential interval, 6.0–14.0 months).
Conclusion A combination of S-1 and CPT-11 showed a good safety profile and can be recommended for further phase II studies in patients
with colorectal cancer. 相似文献
10.
Ho JC Tan EH Leong SS Wang CH Sun Y Li R Wahid MI Jusuf A Liao M Guan Z Handoyo P Huang JS Chan V Luna G Tsang KW Lam WK;Asian-Pacific Collaborative Group 《Respiratory medicine》2003,97(7):796-803
AIMS: To evaluate the efficacy and safety of docetaxel-cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). METHODS: Chemotherapy-na?ve patients with histologically confirmed TNM stage III or IV NSCLC were recruited from 12 Asian trial centers. Patients received docetaxel (75 mg/m2) and cisplatin (75 mg/m2) every 3 weeks for 6 cycles. RESULTS: 130 of 146 patients were evaluable for efficacy (60% stage IV). Three complete and 58 partial responses were observed (overall response rate: 46.9%; 95% CI: 38.3-55.5%). Median time to progression was 6.9 months and median survival was 14.0 months; 1-year survival was 59.5%. Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 69.2%, 6.2% and 18.5% of patients, respectively. Grade 3/4 vomiting was observed in 13.7% and grade 3/4 neurosensory effects were observed in 2.7% of patients. There was one case of treatment-related death due to sepsis. CONCLUSION: Docetaxel-cisplatin is an effective and well-tolerated treatment in Asian patients with NSCLC. 相似文献
11.
多西紫杉醇联合卡铂治疗晚期非小细胞肺癌的疗效观察 总被引:5,自引:1,他引:5
目的观察多西紫杉醇联合卡铂治疗晚期非小细胞肺癌近期疗效及毒副反应。方法47例晚期非小细胞肺癌住院患者给予多西紫杉醇联合卡铂治疗,多西紫杉醇75mg/m2,静滴,d1,卡铂根据AUC5计算用量,静滴,d1,21d为1周期,每个患者均完成2个周期以上,评价疗效和不良反应,并随访生存期。结果47例患者治疗后CR0例、PR24例、NC17例、PD6例,有效率为51.1%。KS评分增加者70.2%(33/47)、稳定21.3%(10/47)、下降8.5%(4/47)。中位生存期9个月(95%CI8~10个月),1年生存率27.1%。最常见的毒副反应为骨髓抑制,全组68.1%(32/47)出现白细胞下降,其中Ⅲ度~Ⅳ度白细胞减少发生率为25.5%,恶心、呕吐29.8%(14/47),脱发87.2%(41/47)。其余毒副反应轻微,均可耐受。结论多西紫杉醇联合卡铂治疗晚期非小细胞肺癌有较好的疗效,毒副反应比较轻微。 相似文献
12.
Pan F Tian J Zhang X Zhang Y Pan Y 《Journal of cancer research and clinical oncology》2011,137(9):1397-1408
Purpose
Previous studies have demonstrated that sunitinib has the anti-tumor activity in human non–small cell lung cancer (NSCLC). This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs. 相似文献13.
Michener CM Peterson G Kulp B Webster KD Markman M 《Journal of cancer research and clinical oncology》2005,131(9):581-584
Purpose To evaluate the efficacy and safety of the combination of carboplatin plus paclitaxel in patients with advanced, metastatic
and recurrent endometrial cancer. Methods Medical records were retrospectively reviewed to identify endometrial cancer patients treated in the Gynecologic Cancer Program
of the Cleveland Clinic with carboplatin/paclitaxel who had both a histologic diagnosis of endometrial adenocarcinoma and
either measurable (CT scan, physical examination) or evaluable (CA-125 criteria) disease. Results From 1994 to 2003, 22 individuals (median age 65 years) meeting the above noted criteria received a total of 23 courses of
carboplatin (AUC 4–6)/paclitaxel (135–175 mg/m2) administered on a 21-day schedule (median six cycles/patient). The overall
response rate was 87% (20/23). The most common toxicity was hematologic. Five patients required dose reductions due to excessive
toxicity (three hematologic, one gastrointestinal, one fatigue). There were no treatment related deaths. With a median follow-up
of 42 months, 13 patients have died of progressive cancer, while four currently have no evidence of disease at the time of
last follow-up. Conclusions The combination of carboplatin plus paclitaxel demonstrates substantial biological activity in endometrial adenocarcinoma.
The safety and efficacy of this regimen makes it an attractive option for first-line chemotherapy in patients with advanced
or recurrent endometrial carcinoma. 相似文献
14.
Baur M van Oosterom AT Diéras V Tubiana-Hulin M Coombes RC Hatschek T Murawsky M Klink-Alakl M Hudec M Dittrich C 《Journal of cancer research and clinical oncology》2008,134(2):125-135
The efficacy and tolerability of docetaxel 100 mg/m2 every 3 weeks as second-line chemotherapy in patients with metastatic
breast cancer was investigated. In addition, the efficacy of a 3-day prophylaxis against cumulative dose-related fluid retention
was examined with methylprednisolone 32 mg twice daily for 3 days starting 12 and 3 h before the docetaxel infusion together
with oral cetirizine 10 mg 12 and 3 h before start of docetaxel for prevention of acute hypersensitivity reactions. According
to the intent to treat-analysis 35% (95%CI: 25; 46) of the 94 patients entered responded to therapy. Their median survival
was 12 months (range 0–20 months). The respective response rate for the 87 patients eligible for response evaluation was 37%
(95%CI: 27; 48). Their median duration of response was 8 months (range 3–12 months), their median time to progression was
4 months (range 1–12 months). The corresponding response rate in the eligible patient cohort with anthracycline-resistant
disease was 28% (95%CI: 15; 45) and increased to 44% (95%CI: 30; 59) in the cohort with non-anthracycline-resistant disease.
Patients with visceral metastases responded in 36% and patients with ≥3 organs involved in 33%. In a retrospective analysis,
the 3-day premedication of corticosteroids and antihistamines proved to be as effective as the established but more toxic
5-day regimen in delaying and preventing the occurrence of docetaxel derived toxicities especially the cumulative fluid retention.
In conclusion, docetaxel represents one of the most active agents for second-line treatment of metastatic breast cancer, especially
for anthracycline-resistant patients. Due to comparable effectiveness of the 5-day regimen which is widely used by others
and the 3-day premedication tested in this trial the latter proved to be more favourable and was therefore recommended for
future therapies. 相似文献
15.
To evaluate the efficacy of systemic ifosfamide, cisplatin (CDDP) combination as first line treatment followed by intraperitoneal (IP) chemotherapy with carboplatin (CBCDA) and etoposide as consolidation in patients with stage III and IV epithelial ovarian cancer. A total of 40 patients with stage III and IV ovarian cancer were entered into the study. Ifosfamide 1 glm2 plus mesna 1 glm2 was given as six hour infusion daily for six days and CDDP 75 mglm2 was given on day seven. Patients completing six cycles of systemic therapy underwent second look laparotomy followed by four cycles of IP chemotherapy with CBCDA 300 mglm2 and etoposide 200 mglm2. Of the 40 patients entering the protocol 27 patients completed six cycles with a complete remission (CR) of 65% and overall response of 67.5%. Twenty-two patients underwent second look laparotomy with pathological CR in ten patients, microscopic disease in seven and macroscopic disease in five. Eleven patients completed four cycles of IP chemotherapy. At 52 months the overall survival (OS) was 36%. The disease free survival (DFS) at 45 months was 38%. Factors affecting OS were ascites (p<0.011), stage (p<0.04), weight change (p<0.017), residual disease (p<0.001), number of chemotherapy cycles (p<0.0001) and IP chemotherapy (p<0.006). Presently 35% patients are alive in CR, 15% are alive with disease, one patient has been lost to follow up while 47.5% have died. Of these four patients had progressive disease, seven relapsed, four died due to treatment related complications and two died in CR due to other causes. Subset analysis of 22 patients who had second look laparotomy and completed four cycles of IP chemotherapy revealed a distinct survival advantage. IFOS+CDDP is an effective combination as first time treatment in advanced ovarian cancer. IP chemotherapy is effective as consolidation and seems to provide a significant survival advantage. Further studies with larger number of patients need to be done to confirm these results. 相似文献
16.
17.
《Respiratory investigation》2014,52(3):190-194
BackgroundAmrubicin (AMR), a new anthracycline agent, has shown promising results for advanced small-cell lung cancer (SCLC), although the efficacy of AMR alone against refractory relapsed SCLC is insufficient. This study was conducted to evaluate the safety and efficacy of the combination of AMR and carboplatin (CBDCA) in patients with refractory relapsed SCLC.MethodsPatients with advanced SCLC who relapsed within 90 days after the completion of first-line chemotherapy received AMR (30 mg/m2, days 1–3) and CBDCA (area under the curve 4.0 mg mL−1 min−1, day 1) every 3 weeks. The primary endpoint of this study was the overall response rate (ORR), and the secondary endpoints were progression-free survival (PFS), overall survival, and the toxicity profile. Assuming that an ORR of 45% in eligible patients would indicate potential usefulness and an ORR of 20% would be the lower limit of interest, with α=0.10 and β=0.10, at least 24 patients were required.ResultsAmong 29 eligible patients, the ORR was 34% (90% confidence interval, 20–48). The median PFS was 3.5 months, whereas the median survival time was 7.3 months. The most common grade 3–4 toxicity was neutropenia (79%), although only one patient (3%) suffered from febrile neutropenia. Non-hematological toxicities were of moderate severity and no treatment-related death was observed.ConclusionsThis is the first prospective study of AMR combined with CBDCA for refractory relapsed SCLC, which was effective and well tolerated. However, further investigation of this regimen is warranted. 相似文献
18.
Background To assess the long-term efficacy and the pattern of failure of concurrent chemoradiotherapy followed by high dose rate (HDR)
brachytherapy for stage T2-3 N0-1 M0 esophageal carcinoma.
Methods Forty-six patients with clinical stage T2-3 N0-1 M0 esophageal cancer received concurrent chemoradiotherapy followed by HDR
brachytherapy. The chemotherapy regimen was a combination of cisplatin 60 mg/m2 on day 1 and fluorouracil 600 mg/m2 continuous infusion from days 1 to 4 during the first and last week of external-beam irradiation. Radiotherapy consisted
of external beam to a total dose of 40–60 Gy (median, 50 Gy) and high dose rate brachytherapy to 8–24 Gy (median, 16 Gy) in
2–4 fractions. External beam was delivered to a field of the primary lesion and the involved nodal lesions. All patients were
followed up for at least 5 years.
Results The 5-year overall survival rate was 28%. The median survival duration was 22 months. The 5-year cause-specific survival rate
was 34% and the median was 22 months. Persistent disease was found in 7 of 46 patients (15%). Of the 39 patients with initial
complete tumor disappearance, locoregional failure occurred ultimately in 13 patients. The ultimate local control rate was
57% (26/46). Three patients were salvaged successfully with surgery. Four patients (9%) had regional recurrence out of the
irradiated fields as first failure site. Four patients (9%) had recurrence 3 years or longer after treatment. Twelve patients
had transient ulcers, which healed spontaneously within a few months. Massive esophageal bleeding, thought to be treatment
related, occurred in 2 patients, leading to death. Severe late toxicity with esophageal ulceration was found in patients receiving
a dose of 16–24 Gy via brachytherapy.
Conclusions Concurrent chemoradiotherapy followed by HDR brachytherapy achieved long-term effective and curative results for stage T2-3
N0-1 M0 esophageal carcinoma. However, severe late toxicity was observed with 16–24 Gy via brachytherapy. We recommend a dose
via HDR brachytherapy should be 12 Gy or less following concurrent chemoradiotherapy. 相似文献
19.
Fedders M Hartmann M Schneider A Kath R Camara O Oelschläger H 《Journal of cancer research and clinical oncology》2007,133(9):619-625
Purpose So far there is no analysis available on the cost effectiveness of the paclitaxel/platinum-analogue combination versus carboplatin
monotherapy with ovarian cancer. Up-to-now only a cost-utility analysis on ovarian carcinoma has been published (Ortega et
al. in Gynecol Oncol 66(3):454–463, 1997), which in addition to the first-line chemotherapy included second-line chemotherapy with effectiveness and cost data in
the analysis. Therefore, within the scope of our study the cost effectiveness of platinum analogues and paclitaxel as first-line
chemotherapy as well as topotecan and liposomal doxorubicin as second-lie chemotherapy was to be determined with epithelial
ovarian carcinoma.
Methods For this purpose a decision-making Markov model was developed which represents the medical and economic consequences of the
administration of paclitaxel and platinum derivatives in first-line chemotherapy and the administration of topotecan and liposomal
doxorubicin in second-line chemotherapy in the treatment of epithelial ovarian carcinoma by means of data from the literature.
Patients were treated either in the early (FIGO stage I–IIa) or advanced stage (FIGO stage IIb–IV).
Results The therapeutic strategy caboplatin followed by topotecan costs 20,123.91 €, the therapeutic strategy carboplatin followed
by liposomal doxorubicin 22,336.57 €, the therapeutic strategy carboplatin/pactlitaxel followed by liposomal topotecan 29,820.64
€ and the therapeutic strategy carboplatin/paclitaxel followed by liposomal doxorubicin 31,560.47 € from the time of diagnosis
until death or survival within 5 years. With lives saved, accordingly of 2.55, 2.70, 2.60 and 2.65 years’ costs amounted to
7,891 €, 8,270.35 €, and 11,453.62 € per year of life saved.
Conclusions Based on the threshold value of social willingness to pay 45,500 € per year of life saved, the therapeutic strategy carboplatin
followed by topotecan, the therapeutic strategy carboplatin followed by liposomal doxorubicin, the therapeutic strategy carboplatin/paclitaxel
followed by topotcan and the therapeutic strategy carboplatin/paclitaxel followed by liposomal doxorubicin can be evaluated
to be cost effective. 相似文献
20.
K. Höffken Kh. Merkle M. Schönfelder G. Anger M. Brandtner K. Ridwelski S. Seeber 《Journal of cancer research and clinical oncology》1998,124(11):627-632
A phase II pilot study of bendamustine as salvage treatment in patients with advanced breast cancer was performed to determine
the objective response rates and make further observations on the toxicity of this drug. A group of 37 patients, pretreated
with chemotherapy for advanced disease, entered the trial. Treatment consisted of 150 mg/m2 bendamustine on days 1 and 2 of a 4-week treatment course. Patients continued to receive treatment until complete remission
and then two further courses, until tumour progression or unacceptable toxicity ensued. A total of 36 patients received at
least one treatment course and were assessable for toxicity; 33 patients were evaluable for treatment results. Dose-limiting
grade 3 and 4 WHO toxicity occurred in 5 and 3 patients respectively; 27% of patients entered complete or partial tumour remission.
The median time to tumour progression was 2 months with a range of 1–14 months. The efficacy of bendamustine was apparently
independent of pretreatment with anthracyclines, suggesting a lack of cross-resistance between bendamustine and anthracyclines.
It can be concluded that bendamustine in the dose and application schedule used here is active in the salvage therapy of women
with advanced breast cancer. The toxicity was acceptable. Future studies have to confirm the data of this pilot trial and
to define the role of bendamustine in the combination chemotherapy of metastatic breast cancer that has been suggested by
previous trials.
Received: 9 April 1998 / Accepted: 24 June 1998 相似文献